摘要
目的:比较3种方案治疗小儿呼吸道感染的经济学效果。方法:采用回顾性调查方法,对阿莫西林/克拉维酸钾(A组)、头孢呋辛钠+利巴韦林(B组)和头孢哌酮/舒巴坦(C组)治疗小儿呼吸道感染进行成本-效果分析。结果:A、B、C组成本分别为855.46、798.90、773.00元,总有效率分别为93.75%、96.00%、95.83%(P>0.05),成本-效果比分别为912.5、832.2、806.6。结论:C组方案较佳。
OBJECTIVE: To compare the pharmacoeconomics outcome of 3 schemes in treating respiratory tract infection (RTI) in children.METHODS: This is a retrospective study in which a cost effectiveness analysis were performed on the following 3 schemes in treating RTI in children:amoxicillin/potassium clavulanate(Group A),cefuroxime plus ribavirin(Group B), and cefoperazone/sulbactam(Group C) .RESULTS: The costs for Group A, B and C were 855.46 yuan, 798.90 yuan and 773.00 yuan, respectively;the effective rates stood at 93.75% ,96.00% and 95.83% ,respectively(P〉0.05),and the cost-effectiveness ratio were 912.5,832.2 and 806.6, respectively.CONCLUSION : Scheme C was superior among the three.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第26期2012-2013,共2页
China Pharmacy
关键词
呼吸道感染
治疗方案
成本-效果分析
Respiratory tract infection
Therapeutic regimes
Cost- effectiveness analysis